datma Unveils Federated Biomarker Explorer for Health Systems, Enabling Visibility Into Data Demand Without Data Sharing or Commitment
New offering gives health systems a way to determine whether their healthcare data aligns with pharmaceutical demand before engaging or dedicating resources.
September 16, 2025 — Beaverton, OR — data, a leader in federated real-world data access, today announced the Federated Biomarker Explorer for Health Systems, a new tool that gives hospitals, cancer centers, and labs a way to validate pharmaceutical demand for their data before committing to a data partnership or investing internal effort. Health systems interested in previewing pharma demand for their data can register now for early access.
This latest application for health systems complements the Federated Biomarker Explorer for Pharma, launched in July, which allows pharmaceutical and life sciences users to assess real-world data feasibility across datma’s federated network. Together, these offerings will enable data custodians and data consumers to validate alignment earlier and more efficiently, without risk or obligation.
Health data plays a large role in oncology research and precision medicine, but that doesn’t always translate into measurable return. In many data sharing arrangements, health systems are asked to invest resources up front without knowing if their data will be used, when it might generate value, or whether it aligns with active pharmaceutical needs. When usage is unclear, so is return on investment, leaving institutions uncertain about when, or if, their participation will pay off.
“Health systems shouldn’t have to guess whether their data has immediate value to pharma,” said Robin Edison, VP of Product at datma. “Now they don’t. This tool lets them know exactly when their data is needed, and when participating will create immediate value.”
A More Strategic Way to Engage
Participating health systems provide a high-level summary of their available data, such as cancer types, biomarker findings, and cohort sizes. No patient data is shared, and no technical integration or legal agreement is required at this stage. These summaries are made visible in the Federated Biomarker Explorer to vetted pharma and life sciences users conducting feasibility searches for real-world data. . When a match is identified, datma alerts the health system directly, and health systems have a clear opportunity to participate in datma.FED with immediate return on demand already in place. From there, the institution decides whether to engage. Participation is optional and can be updated or withdrawn at any time.
Eliminating Uncertainty in Data Partnerships
Many health systems have explored data sharing partnerships only to face unclear timelines, limited usage, or stalled outcomes. Some have made early investments with real-world data aggregators and seen little or no return.
The Federated Biomarker Explorer reverses that dynamic by allowing institutions to act only when real demand has been confirmed. It shortens the path to value while eliminating the risk of wasted internal effort.
“This model creates alignments before any commitment,” said Noah Nasser, CEO of datma. “Health systems can now engage with confidence, knowing there’s a real use case.”
Validating Demand from Both Sides
With the launch of both the Pharma and Health System Federated Biomarker Explorer, datma now supports bidirectional validation across its federated network. Pharma teams can evaluate real-world data coverage to assess feasibility. Health systems can see when their data is in demand before engaging. Neither party is asked to move forward until there’s a clear, confirmed signal, helping both sides reduce risk and act with greater confidence.
The Federated Biomarker Explorer for Health Systems is available for early access registration today. To learn more and join the early access list, visit https://www.datma.com/health-trial.
About datma
datma is transforming how healthcare is accessed and shared through a secure, federated ecosystem that enables collaboration between data custodians and data consumers. Headquartered in Beaverton, OR, datma’s flagship platform, datma.FED powers a two sided marketplace for real-world healthcare data that supports compliant, privacy-preserving collaboration without requiring data to move or sacrificing institutional control. datma.FED leverages advanced data storage, AI-enabled tools for harmonizing multimodal datasets, and federated query capabilities. The platform is designed to maximize data utility while requiring minimal technical effort from participating organizations. It allows data custodians to generate secondary revenue streams and reinvest in innovation while maintaining control over their data, while helping data consumers access diverse, high-quality, de-identified data that augments existing datasets and supports evidence generation at scale. By addressing longstanding challenges in data access, privacy, and utility, datma.FED supports the evidence generation needed to advance precision medicine. For more information, visit www.datma.com.
Media Contact:
Vikki Herrera
Oak Street Communications
vikki@oakstreetcommunications.com
